The vitamin E analog, alpha-tocopheryloxyacetic acid enhances the anti-tumor activity of trastuzumab against HER2/neu-expressing breast cancer

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Hahn, Tobias ^a   Bradley Dunlop, Deborah J ^b   Hurley, Laurence H ^c,d   Von Hoff, Daniel ^e   Gately, Stephen ^e   Mary, Disis L ^f   Lu, Hailing ^f   Penichet, Manuel L ^g,h   Besselsen, David G ^c   Cole, Brook B ^a   Meeuwsen, Tanisha ^a   Walker, Edwin ^a   Akporiaye, Emmanuel T ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ARIZONA   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; RITUXIMAB; TRASTUZUMAB; 2,5,7,8 TETRAMETHYL 2R (4R,8R,12 TRIMETHYLTRIDECYL)CHROMAN 6 YLOXY ACETIC ACID; 2,5,7,8-TETRAMETHYL-2R-(4R,8R,12-TRIMETHYLTRIDECYL)CHROMAN-6-YLOXY ACETIC ACID; ANTINEOPLASTIC AGENT; ANTIOXIDANT; MONOCLONAL ANTIBODY; PEPTIDE FRAGMENT; TOCOPHEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER REGRESSION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; BIOLOGICAL MODEL; BREAST TUMOR; CELL SURVIVAL; DRUG EFFECT; FLOW CYTOMETRY; METABOLISM; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DRUG SYNERGISM; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; TOCOPHEROLS;

EID: 80055120461     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-471     Document Type: Article

References (41)

1. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. Jama 2005, 294:56-65. 10.1001/jama.294.1.56, 15998891.
2. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Jama 2009, 301:39-51. 10.1001/jama.2008.864, 19066370.
3. Lawson KA, Anderson K, Menchaca M, Atkinson J, Sun L, Knight V, Gilbert BE, Conti C, Sanders BG, Kline K. Novel vitamin E analogue decreases syngeneic mouse mammary tumor burden and reduces lung metastasis. Mol Cancer Ther 2003, 2:437-444.
4. Anderson K, Simmons-Menchaca M, Lawson KA, Atkinson J, Sanders BG, Kline K. Differential response of human ovarian cancer cells to induction of apoptosis by vitamin E Succinate and vitamin E analogue, alpha-TEA. Cancer Res 2004, 64:4263-4269. 10.1158/0008-5472.CAN-03-2327, 15205340.
5. Lawson KA, Anderson K, Snyder RM, Simmons-Menchaca M, Atkinson J, Sun LZ, Bandyopadhyay A, Knight V, Gilbert BE, Sanders BG, Kline K. Novel vitamin E analogue and 9-nitro-camptothecin administered as liposome aerosols decrease syngeneic mouse mammary tumor burden and inhibit metastasis. Cancer Chemother Pharmacol 2004, 54:421-431. 10.1007/s00280-004-0817-y, 15197487.
6. Hahn T, Fried K, Hurley LH, Akporiaye ET. Orally active {alpha}-tocopheryloxyacetic acid suppresses tumor growth and multiplicity of spontaneous murine breast cancer. Mol Cancer Ther 2009, 8:1570-1578. 10.1158/1535-7163.MCT-08-1079, 19509249.
7. Hahn T, Szabo L, Gold M, Ramanathapuram L, Hurley LH, Akporiaye ET. Dietary Administration of the Proapoptotic Vitamin E Analogue {alpha}-Tocopheryloxyacetic Acid Inhibits Metastatic Murine Breast Cancer. Cancer Res 2006, 66:9374-9378. 10.1158/0008-5472.CAN-06-2403, 17018590.
8. Yu W, Tiwary R, Li J, Park SK, Jia L, Xiong A, Simmons-Menchaca M, Sanders BG, Kline K. alpha-TEA induces apoptosis of human breast cancer cells via activation of TRAIL/DR5 death receptor pathway. Mol Carcinog 2010, 49:964-973. 10.1002/mc.20681, 20886583.
9. Neuzil J, Dong LF, Ramanathapuram L, Hahn T, Chladova M, Wang XF, Zobalova R, Prochazka L, Gold M, Freeman R, Turanek J, Akporiaye ET, Dyason JC, Ralph SJ. Vitamin E analogues as a novel group of mitocans: anti-cancer agents that act by targeting mitochondria. Mol Aspects Med 2007, 28:607-645. 10.1016/j.mam.2007.02.003, 17499351.
10. Kline K, Lawson KA, Yu W, Sanders BG. Vitamin E and cancer. Vitam Horm 2007, 76:435-461.
11. Neuzil J, Weber T, Schroder A, Lu M, Ostermann G, Gellert N, Mayne GC, Olejnicka B, Negre-Salvayre A, Sticha M, Coffey RJ, Weber C. Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. Faseb J 2001, 15:403-415. 10.1096/fj.00-0251com, 11156956.
12. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986, 319:226-230. 10.1038/319226a0, 3945311.
13. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 1987, 237:178-182. 10.1126/science.2885917, 2885917.
14. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54:105-115.
15. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
16. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712. 10.1126/science.2470152, 2470152.
17. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. Gene 1995, 159:19-27. 10.1016/0378-1119(94)00866-Q, 7607568.
18. Hudis CA. Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007, 357:39-51. 10.1056/NEJMra043186, 17611206.
19. Untch M, Gelber RD, Jackisch C, Procter M, Baselga J, Bell R, Cameron D, Bari M, Smith I, Leyland-Jones B, de Azambuja E, Wermuth P, Khasanov R, Feng-Yi F, Constantin C, Mayordomo JI, Su CH, Yu SY, Lluch A, Senkus-Konefka E, Price C, Haslbauer F, Sahui TS, Srimuninnimit V, Colleoni M, Coates AS, Piccart-Gebhart MJ, Goldhirsch A. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008,
20. Orman JS, Perry CM. Trastuzumab: in HER2 and hormone receptor co-positive metastatic breast cancer. Drugs 2007, 67:2781-2789. 10.2165/00003495-200767180-00009, 18062723.
21. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett 2006, 232:123-138. 10.1016/j.canlet.2005.01.041, 16458110.
22. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000, 6:443-446. 10.1038/74704, 10742152.
23. Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A. Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 2004, 10:5650-5655. 10.1158/1078-0432.CCR-04-0225, 15355889.
24. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 2001, 61:5090-5101.
25. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, Fendly B, Kerbel RS. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997, 151:1523-1530. 1858348, 9403702.
26. Zhang S, Lawson KA, Simmons-Menchaca M, Sun L, Sanders BG, Kline K. Vitamin E analog alpha-TEA and celecoxib alone and together reduce human MDA-MB-435-FL-GFP breast cancer burden and metastasis in nude mice. Breast Cancer Res Treat 2004, 87:111-121. 10.1023/B:BREA.0000041593.69178.57, 15377836.
27. Yu W, Shun MC, Anderson K, Chen H, Sanders BG, Kline K. alpha-TEA inhibits survival and enhances death pathways in cisplatin sensitive and resistant human ovarian cancer cells. Apoptosis 2006, 11:1813-1823. 10.1007/s10495-006-9234-5, 16850165.
28. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GC, Schiff R, Digiovanna MP, Wang CX, Hilsenbeck SG, Osborne CK, Allred DC, Elledge R, Chang JC. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005, 23:2460-2468. 10.1200/JCO.2005.00.661, 15710948.
29. Wang P, Yu W, Hu Z, Jia L, Iyer VR, Sanders BG, Kline K. Involvement of JNK/p73/NOXA in vitamin E analog-induced apoptosis of human breast cancer cells. Mol Carcinog 2008, 47:436-445. 10.1002/mc.20400, 18058804.
30. Hahn T, Jagadish B, Mash EA, Garrison K, Akporiaye ET. Alpha-tocopheryloxyacetic acid: a novel chemotherapeutic that stimulates the anti-tumor immune response. Breast Cancer Res 2011, 13:R4. 10.1186/bcr2808, 3109570, 21232138.
31. Kline K, Sanders BG, Hurley L, Gardner R, Menchaca M, Yu W, Ramanan PN, Liu S, Israel K. Preparation of tocopherols, tocotrienols, other chroman and side chain derivatives for use as antitumor agents and for inducing cell apoptosis. PCT Int Appl 2000,
32. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo. Oncogene 1988, 2:273-277.
33. Knutson KL, Almand B, Dang Y, Disis ML. Neu antigen-negative variants can be generated after neu-specific antibody therapy in neu transgenic mice. Cancer Res 2004, 64:1146-1151. 10.1158/0008-5472.CAN-03-0173, 14871850.
34. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63. 10.1016/0022-1759(83)90303-4, 6606682.
35. ImageJ. , http://imagej.nih.gov/ij/
36. Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 2003, 17:590-603.
37. Jia L, Yu W, Wang P, Sanders BG, Kline K. In vivo and in vitro studies of anticancer actions of alpha-TEA for human prostate cancer cells. Prostate 2008, 68:849-860. 10.1002/pros.20750, 18324647.
38. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998, 58:2825-2831.
39. Treish I, Schwartz R, Lindley C. Pharmacology and therapeutic use of trastuzumab in breast cancer. Am J Health Syst Pharm 2000, 57:2063-2076. quiz 2077-2069.
40. Montemurro F, Valabrega G, Aglietta M. Trastuzumab-based combination therapy for breast cancer. Expert Opin Pharmacother 2004, 5:81-96. 10.1517/14656566.5.1.81, 14680438.
41. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer 2006, 94:259-267. 10.1038/sj.bjc.6602930, 2361112, 16404427.